Generic Name and Formulations:
House dust mite allergen extract (Dermatophagoides farinae, Dermatophagoides pteronyssinus) 12 SQ-HDM; sublingual tabs.
Merck & Co., Inc.
Indications for ODACTRA:
House dust mite-induced allergic rhinitis, with or without conjunctivitis, confirmed by in vitro testing for IgE antibodies to Dermatophagoides farinae or Dermatophagoides pteronyssinus house dust mites, or skin testing to licensed house dust mite allergen extracts. Not for immediate relief of allergic symptoms.
Give 1st dose under physician supervision; observe ≥30mins for any signs/symptoms of severe allergic reaction; if tolerated, subsequent doses may be taken at home. 18–65yrs: 1 tab daily. Allow complete dissolution under the tongue before swallowing. Avoid food or beverage for 5 mins after dosing. Wash hands after handling tab.
<18yrs: not established.
Severe, unstable or uncontrolled asthma. History of any severe systemic or local allergic reaction to sublingual allergen immunotherapy. History of eosinophilic esophagitis.
Risk of severe allergic reactions (eg, anaphylaxis, laryngopharyngeal swelling); discontinue if occurs. Prescribe auto-injectable epinephrine for emergency use. Underlying conditions that may reduce survival of a serious allergic reaction after epinephrine use (eg, markedly compromised lung function, unstable angina, recent MI, significant arrhythmia, uncontrolled HTN). Upper airway compromise: consider discontinuing if persistent adverse reactions in the mouth or throat develops. Withhold therapy in acute asthma exacerbation; consider discontinuing if recurrent. Interrupt therapy for oral inflammation or wounds to allow complete healing. Elderly (>65yrs). Pregnancy. Nursing mothers.
Concomitant other allergen immunotherapy: not studied; may increase risk of local or systemic adverse reactions. Avoid concomitant drugs that can potentiate or inhibit effects of epinephrine (eg, beta-adrenergic blockers, alpha-adrenergic blockers, ergot alkaloids, TCAs, levothyroxine, MAOIs, chlorpheniramine, diphenhydramine, [cardiac glycosides, diuretics; monitor for arrhythmias]).
Throat irritation/tickle, mouth or ear itching, swelling (uvula/back of mouth, lips, tongue, throat), nausea, tongue pain, tongue or mouth ulcer/sore, stomach pain, taste alteration; eosinophilic esophagitis (discontinue if occurs).
Neurology Advisor Articles
- FDA Approves Aimovig for Migraine Prevention
- Prediction Algorithm Stratifies ICH Patients at Risk for Hematoma Expansion
- Sports-Related Concussion Outcomes Predicted With Serum Neurofilament Light
- FDA: Lamotrigine Linked to Potentially Life-Threatening Adverse Reaction
- Psychological Therapies May Help Older Adults With Chronic Pain
- Amyloid Positivity Increases Risk for Cognitive Impairment in Dementia-Free Patients
- Valproic Acid-Related Adverse Fetal Outcomes May Be Linked to Placental Effects
- Risk of Dementia Up for Older Adults With Lowest Wealth
- Language Used in Medical Record Can Affect Patient Care
- Mortality in Alzheimer Disease Not Strongly Associated With Antipsychotics